Source: BioPortfolio

Acucela: Acucela gets European orphan designation for emixustat to treat Stargardt disease

In January 2017 Acucela had received orphan drug designation from the US Food and Drug Administration FDA for emixustat to treat Stargardt disease. Stargardt disease is a rare The post Acucela gets European orphan designation for emixustat to treat Stargar...

Read full article »
Est. Annual Revenue
$5.0-25M
Est. Employees
25-100
Ryo Kubota's photo - Chairman & CEO of Acucela

Chairman & CEO

Ryo Kubota

CEO Approval Rating

85/100

Read more